Cancer vaccine - Icon Genetics

Drug Profile

Cancer vaccine - Icon Genetics

Alternative Names: Autologous idiotype vaccine; Cancer vaccine autologous; Cancer vaccine Bayer; Follicular lymphoma autologous vaccine

Latest Information Update: 13 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer Innovation GmbH
  • Developer Bayer Innovation GmbH; Stellar Biotechnologies
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Follicular lymphoma

Most Recent Events

  • 01 Oct 2013 Bayer completes a phase I study in Follicular lymphoma in USA (NCT01022255; PMP00025-01)
  • 04 Sep 2012 Bayer completes enrolment in its Phase-I trial for Follicular lymphoma in USA (NCT01022255)
  • 07 Dec 2010 Bayer has gained use of technology relating to production of immunogenic proteins from its collaboration with Stellar Biotechnologies for application in its autologous idiotype vaccine for non-Hodgkin's lymphoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top